Algorithm for Cervix Carcinoma Screening in CZ Using the Detection of HPV DNA and CINtec Plus
Launched by AESKULAB PATHOLOGY PRAGUE · Oct 11, 2022
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
Cervix carcinoma has been a serious, long-term issue in the Czech Republic. About 1,000 new cases are diagnosed every year and about 400 female patients die as a result of the disease. More than 20,000 women in the Czech Republic live with a history of cervix carcinoma therapy and the potential risk of its recurrence. Although the past years have been marked with effective organisational changes in cervix carcinoma screening thanks to which a decreasing trend of its incidence can be observed, there is a lack of substantial impact on the occurrence of advanced stages of the disease and morta...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Informed consent signature
- • Age 30 - 60
- • Screening (not reviewing after previous abnormal cytological finding)
- • Sampling of gravid women possible
- Exclusion Criteria:
- • Refusal to take part
About Aeskulab Pathology Prague
Aeskulab Pathology Prague is a leading clinical trial sponsor dedicated to advancing medical research through high-quality diagnostic services and innovative pathology solutions. Based in Prague, the organization specializes in providing comprehensive pathology expertise, facilitating the development and evaluation of new therapies across various therapeutic areas. With a commitment to scientific excellence and regulatory compliance, Aeskulab collaborates with pharmaceutical and biotechnology companies to enhance patient outcomes through rigorous clinical trials and robust data analysis. Their multidisciplinary team of experienced professionals ensures that each study is conducted with integrity, precision, and a focus on improving healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Praha, Czech Republic, Czechia
Patients applied
Trial Officials
Markéta Trnková, MD
Principal Investigator
Aeskulab Patologie, ks
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials